Open Peer Review on Qeios

HLA-A*0201-Restricted VEGFR1-VEGFR2 Multipeptide Vaccine

National Cancer Institute

Source

National Cancer Institute. <u>HLA-A*0201-Restricted VEGFR1-VEGFR2 Multipeptide Vaccine</u>. NCI Thesaurus. Code C77905.

A cancer vaccine containing two HLA-A*0201-restricted peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from: vascular endothelial growth factor receptors (VEGFR) 1 and 2. Upon administration, HLA-A*0201-restricted VEGFR1-VEGFR2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing VEGFR 1 and 2 peptides, resulting in tumor cell lysis and decreased tumor growth. HLA-A*0201 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*0201 may improve antigenic peptide immunogenicity.